HER2 testing and targeted therapy are well established in the management of breast cancer. Now, a study by Chiu and colleagues reports that HER3 status is also an important prognostic marker of ...

Zenocutuzumab is a first-in-class, humanized, full-length immunoglobulin G1 bispecific antibody that targets HER2 and HER3 directly. After docking on HER2, the drug blocks HER2-HER3 dimerization and ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Zenocutuzumab (Bizengri), a bispecific antibody against HER2 and HER3, showed efficacy in patients with advanced NRG1 ...

HER3 is expressed in more than 80% of EGFR-mutant ... AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab deruxtecan) – which is already on the market for HER2-positive ...

HER3 is expressed in more than 80% of EGFR-mutant ... Meanwhile, Daiichi Sankyo and AZ – its partner for approved HER2-targeting ADC Enhertu (trastuzumab deruxtecan) and investigational TROP2 ...

Another uses a target with high expression on tumor cells, such as HER2, for high-affinity binding with one arm. “With the other arm, one can zoom in and block a molecule such as HER3 that is ...

The most probable forces of HRG–HER3 and HRG–HER3/HER2 under different conditions. Forces were measured at different loading rates for HRG-modified tips and the cells expressing only HER3 ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...